CD8A and primary cutaneous T-cell non-Hodgkin lymphoma: Therefore, increased levels of CD8+ T cells in CTCL serve as a promising criterion for predicting patient survival and supporting treatment decisions, and inclusion of patients in randomized controlled trials10.